Literature DB >> 9834275

Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats.

S Seitz1, U A Boelsterli.   

Abstract

BACKGROUND & AIMS: Enterohepatic recirculation of nonsteroidal anti-inflammatory drugs is a critical factor in the pathogenesis of intestinal injury, but the underlying mechanism of toxicity remains obscure. The aim of this study was to examine the role of diclofenac acyl glucuronide, which is the major biliary metabolite and is chemically reactive, in the precipitation of small intestinal ulceration.
METHODS: Hepatocanalicular conjugate export pump-deficient (TR-) rats were used to selectively block diclofenac enterohepatic circulation without interrupting bile flow. Bile from diclofenac-treated normal rats was orally transferred to wild-type and TR- rats, and the extent of ulcer formation was compared with that induced by control bile containing free diclofenac. The effect of induction of hepatic diclofenac glucuronosyltransferase on the severity of diclofenac-induced ulceration was also determined.
RESULTS: TR- rats were refractory to diclofenac given either intraperitoneally or perorally. However, transfer of bile containing diclofenac glucuronide significantly increased the extent of ulcer formation in both normal and TR- rats. Moreover, induction of glucuronosyltransferase aggravated intestinal ulceration.
CONCLUSIONS: The reactive acyl glucuronide of diclofenac, or the acyl glucuronide of one of its oxidative metabolites, is directly involved in the pathogenesis of small intestinal injury.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9834275     DOI: 10.1016/s0016-5085(98)70026-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  26 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats.

Authors:  D R H Huntjens; A Strougo; A Chain; A Metcalf; S Summerfield; D J M Spalding; M Danhof; O Della Pasqua
Journal:  Br J Pharmacol       Date:  2008-01-14       Impact factor: 8.739

Review 3.  Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy.

Authors:  John L Wallace
Journal:  World J Gastroenterol       Date:  2013-03-28       Impact factor: 5.742

4.  Multidrug Resistance-Associated Protein 3 Plays an Important Role in Protection against Acute Toxicity of Diclofenac.

Authors:  Renato J Scialis; Iván L Csanaky; Michael J Goedken; José E Manautou
Journal:  Drug Metab Dispos       Date:  2015-04-20       Impact factor: 3.922

5.  Elucidation of the Mechanisms through Which the Reactive Metabolite Diclofenac Acyl Glucuronide Can Mediate Toxicity.

Authors:  Renato J Scialis; José E Manautou
Journal:  J Pharmacol Exp Ther       Date:  2016-02-11       Impact factor: 4.030

6.  Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics.

Authors:  Kyle S Saitta; Carmen Zhang; Kang Kwang Lee; Kazunori Fujimoto; Matthew R Redinbo; Urs A Boelsterli
Journal:  Xenobiotica       Date:  2013-07-05       Impact factor: 1.908

Review 7.  Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies.

Authors:  Urs A Boelsterli; Matthew R Redinbo; Kyle S Saitta
Journal:  Toxicol Sci       Date:  2012-10-22       Impact factor: 4.849

8.  Intrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one?

Authors:  Robert A Roth; Patricia E Ganey
Journal:  J Pharmacol Exp Ther       Date:  2009-12-17       Impact factor: 4.030

9.  Ciprofloxacin blocked enterohepatic circulation of diclofenac and alleviated NSAID-induced enteropathy in rats partly by inhibiting intestinal β-glucuronidase activity.

Authors:  Ze-Yu Zhong; Bin-Bin Sun; Nan Shu; Qiu-Shi Xie; Xian-Ge Tang; Zhao-Li Ling; Fan Wang; Kai-Jing Zhao; Ping Xu; Mian Zhang; Ying Li; Yang Chen; Li Liu; Lun-Zhu Xia; Xiao-Dong Liu
Journal:  Acta Pharmacol Sin       Date:  2016-05-16       Impact factor: 6.150

Review 10.  Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents.

Authors:  Parth J Parekh; Edward C Oldfield; David A Johnson
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.